A Spanish startup has become one of only four companies authorised by Spain’s medicines regulator to cultivate medical cannabis, positioning itself to supply export markets in the UK and Germany from a pharmaceutical-grade indoor facility in the Ribera region of Burgos.
Taima Growth received its cultivation licence from the Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) after more than seven years of development.
As part of this lengthy process, Taima was required to have pre-agreed contracts with authorised importers in destination countries, a qualified technical team and compliant facilities in place before the regulator would act.
“The process has been very difficult, but we have achieved it,” said Mo Alyasini, the company’s founder and Chief Executive.
Before commercial sales can begin, Taima must complete validation of three production batches that demonstrate full homogeneity and consistency in accordance with AEMPS standards. Once cleared, the company intends to export dried cannabis flower to importers in the UK and Germany, the two largest established markets for medical cannabis in Europe, and already the destination for the majority of Spain’s licensed cannabis production.
READ MORE…
According to the company, more than €3m has been invested in the project to date, secured from Spanish investors with backgrounds in agriculture, renewable energy and financial services.
Taima’s facility, selected after evaluating more than 200 potential sites across Spain, is a fully controlled indoor environment in which lighting, temperature, humidity and nutrient delivery are continuously monitored and automated.
It is capable of supporting three to five harvests per year and allows the company to deliver the batch-to-batch consistency required by pharmaceutical buyers.
“Our objective was never to become the biggest producer,” Alyasini added. “We wanted to build one of the highest-quality cultivation platforms in Europe.”
The company currently employs six specialists, including quality and production managers with international experience in Uruguay and Portugal. Headcount is expected to reach approximately ten once batch validation is complete. Management has set an initial production target of approximately 1,250 kg annually, with a longer-term ambition of up to nine tonnes.
Spain currently restricts domestic dispensation of cannabis to compounding pharmacy formats, and on 9 June 2026, Secretary of State for Health Javier Padilla confirmed before the Senate’s Joint Commission on Addiction that recreational legalisation is ‘not, by any means, in the plans’ and that the government’s sole framework remains Royal Decree 903/2025.
